Phase 3
N=123
A Safety Study of AQUAVAN® (Fospropofol Disodium) Injection for Sedation During Minor Surgical Procedures.
Procedural Sedation
Bottom Line
View on ClinicalTrials.gov: NCT00327392 ↗Enrolled (actual)
123
Serious AEs
3.3%
Results posted
Jun 2012
Primary outcome: Primary: Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures — 1; 1; 1; 1 particpants
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 3
- Interventions
- AQUAVAN® (fospropofol disodium) Injection (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Eisai Inc.
- Primary completion
- —
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Incidence of Airway Assistance in Patients Undergoing Minor Surgical Procedures |
1; 1; 1; 1; 1; 2 | — |
Summary
Very often patients receive medications before a diagnostic, therapeutic, or surgical procedure to help them relax, keep them calm, and to relieve them from pain. This is called procedural sedation. With respect to minimal-to-moderate procedural sedation for minor surgical procedures, a patient is first given a pain-relief medication (analgesic) and then a medication to help him/her relax and keep calm (sedative). AQUAVAN is a chemically modified form of propofol, a commonly-used sedative drug. AQUAVAN acts like a slow release version of propofol, and is being studied to see if it can safely keep patients calm and relaxed during their medical procedure and then allow for rapid and clear-headed recovery.
Eligibility Criteria
- Number of sites/patients: Approximately 18 sites and 125 patients.
Inclusion Criteria
- Patient must be able to understand, either orally or in writing, and be able to consent and complete the required assessments and procedures.
- Patient provides signed/dated Informed Consent and Health Insurance Portability and Accountability Act (HIPAA) of 1996 authorization after receiving a full explanation of the extent and nature of the study.
- Patient must be at least 18 years of age and undergoing one of the specified minor surgical procedures at the time of screening.
- If female, patient must be surgically sterile, postmenopausal, or not pregnant or lactating and must have been using an acceptable method of birth control for at least 1 month prior to dosing, with a negative urine pregnancy test result at screening and predose.
- Patient meets American Society of Anesthesiologists (ASA) Physical Classification System status of P1 to P4.
Exclusion Criteria
- Patient has a history of allergic reaction or hypersensitivity to any anesthetic agent or opioid.
- Patient does not meet nils per os (NPO) status per ASA guidelines or institution's guideline.
- Patient has a Mallampati Classification Score of 4; or a Mallampati Classification Score of 3 and a thyromental distance <4 cm, or for any other reason has a difficult airway, in the opinion of the Principal Investigator.
- Patient has an abnormal, clinically significant 3-lead ECG finding at predosing period.
- Patient has participated in an investigational drug study within 1 month prior to study start.
- Patient is unwilling to adhere to pre- and postprocedural instructions.
- Patient for whom the use of fentanyl citrate injection (fentanyl) is contraindicated.
Data sourced from ClinicalTrials.gov (NCT00327392). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.